Endo to Acquire BioSpecifics for ~ $540M

 Endo to Acquire BioSpecifics for ~ $540M

Endo to Acquire BioSpecifics for ~ $540M

Shots:

  • Endo to acquire all the outstanding shares of BioSpecifics for $88.50/ share in cash, making a total deal value of $540M. The transaction is expected to close in late 2020 while Endo expects to fund the transaction with cash on hand
  • BioSpecifics receives a royalty stream related to Endo’s collagenase-based therapies, which include Xiaflex for Dupuytren’s contracture and Peyronie’s disease, and Qwo for cellulite, which is expected to be launched by Endo in spring 2021
  • Endo’s acquisition subsidiary will be merged into BioSpecifics, and the remaining shares of BioSpecifics will be canceled and converted into the right to receive the same consideration payable pursuant to the tender offer

Click here ­to­ read full press release/ article | Ref: PRNewswire | Image: Seeking Alpha

Tuba Khan

Tuba Khan is Senior Editor at PharmaShots. She is curious, creative, and passionate about recent updates and innovation in the Life sciences industry. She covers Biopharma, MedTech, and Digital health segments. Tuba also has an experience of digital and social media marketing and runs the campaigns independently. She can be contacted on tuba@pharmashots.com

Related post